---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-103780"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:25:31.130852+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Incannex updates on Phase 2 results for IHL-42X and PSX-001; ATM shares unchanged since Aug 2025

## Summary
- IHL-42X Phase 2 OSA trial showed up to 83% reduction in AHI; 57.6% of participants reported improvement (78.6% low dose).
- PSX-001 Phase 2 GAD trial met primary endpoint HAM-A and multiple secondary measures with sustained relief over 11 weeks, no SAEs.
- ATM facility not utilized since Aug 28, 2025; total shares outstanding unchanged at 347,705,507.
- Company prioritizing FDA engagement for pivotal development of IHL-42X and PSX-001, and exploring partnerships.

## SEC filing metadata
- accession: 0001213900-25-103780
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390025103780/0001213900-25-103780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390025103780/ea0262765-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-103780
- JSON: https://secwatch.observer/filing/0001213900-25-103780.json
- Plain text: https://secwatch.observer/filing/0001213900-25-103780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.